Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Analysis of Solvency Ratios
Quarterly Data

Beginner level

Solvency ratios also known as long-term debt ratios measure a company’s ability to meet long-term obligations.

Solvency Ratios (Summary)

Regeneron Pharmaceuticals Inc., solvency ratios (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Debt Ratios
Debt to equity 0.24 0.06 0.06 0.07 0.07 0.08 0.08 0.09 0.10 0.11 0.11 0.12 0.13 0.15 0.11 0.09 0.09 0.10 0.10 0.12 0.12 0.16
Debt to capital 0.20 0.06 0.06 0.06 0.07 0.07 0.07 0.08 0.09 0.10 0.10 0.10 0.11 0.13 0.10 0.08 0.08 0.09 0.09 0.11 0.10 0.14
Debt to assets 0.15 0.05 0.05 0.05 0.05 0.06 0.06 0.07 0.07 0.08 0.08 0.08 0.09 0.09 0.07 0.06 0.06 0.06 0.06 0.08 0.09 0.11
Financial leverage 1.59 1.30 1.34 1.33 1.35 1.36 1.34 1.37 1.38 1.43 1.43 1.44 1.47 1.61 1.57 1.52 1.52 1.57 1.53 1.57 1.36 1.41
Coverage Ratios
Interest coverage 108.12 90.22 81.43 72.82 69.19 86.34 91.55 91.46 93.35 93.76 83.75 85.15 103.77 119.78 185.82 158.42 135.89 120.37 87.03 — — —

Based on: 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-05), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07).

Solvency ratio Description The company
Debt to equity ratio A solvency ratio calculated as total debt divided by total shareholders’ equity. Regeneron Pharmaceuticals Inc.’s debt to equity ratio improved from Q4 2019 to Q1 2020 but then deteriorated significantly from Q1 2020 to Q2 2020.
Debt to capital ratio A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. Regeneron Pharmaceuticals Inc.’s debt to capital ratio improved from Q4 2019 to Q1 2020 but then deteriorated significantly from Q1 2020 to Q2 2020.
Debt to assets ratio A solvency ratio calculated as total debt divided by total assets. Regeneron Pharmaceuticals Inc.’s debt to assets ratio improved from Q4 2019 to Q1 2020 but then deteriorated significantly from Q1 2020 to Q2 2020.
Financial leverage ratio A solvency ratio calculated as total assets divided by total shareholders’ equity. Regeneron Pharmaceuticals Inc.’s financial leverage ratio decreased from Q4 2019 to Q1 2020 but then increased from Q1 2020 to Q2 2020 exceeding Q4 2019 level.
Solvency ratio Description The company
Interest coverage ratio A solvency ratio calculated as EBIT divided by interest payments. Regeneron Pharmaceuticals Inc.’s interest coverage ratio improved from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.

Debt to Equity

Regeneron Pharmaceuticals Inc., debt to equity calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in thousands)
Debt 1,500,000  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Finance lease liabilities, current portion —  —  —  —  —  —  —  —  —  —  —  —  —  7,200  129,557  —  —  —  —  —  —  — 
Finance lease liabilities, excluding current portion 715,900  715,200  713,900  712,700  711,300  709,900  708,500  707,203  705,903  704,645  703,453  702,317  701,173  700,407  351,569  382,228  361,523  362,230  362,919  364,144  357,687  328,394 
Convertible senior notes —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  30,723  30,360  144,082 
Total debt 2,215,900  715,200  713,900  712,700  711,300  709,900  708,500  707,203  705,903  704,645  703,453  702,317  701,173  707,607  481,126  382,228  361,523  362,230  362,919  394,867  388,047  472,476 
 
Stockholders’ equity 9,057,400  12,133,000  11,089,700  10,504,400  9,755,900  9,444,700  8,757,300  7,868,300  7,186,426  6,567,644  6,144,078  6,051,593  5,520,738  4,866,021  4,449,245  4,491,247  4,076,506  3,765,082  3,654,837  3,296,867  3,338,458  2,971,430 
Solvency Ratio
Debt to equity1 0.24 0.06 0.06 0.07 0.07 0.08 0.08 0.09 0.10 0.11 0.11 0.12 0.13 0.15 0.11 0.09 0.09 0.10 0.10 0.12 0.12 0.16
Benchmarks
Debt to Equity, Competitors2
Abbott Laboratories 0.64 0.60 0.58 0.60 0.61 0.62 0.64 0.77 0.68 0.70 0.90 0.75 0.76 0.76 1.07 0.41 0.43 0.41 0.42 0.40 0.38 0.41
AbbVie Inc. 5.94 — — — — — — — — 10.49 7.33 5.65 6.20 7.39 7.95 5.77 6.71 6.87 8.03 6.61 5.65 11.09
Allergan PLC — 0.34 0.39 0.39 0.38 0.38 0.37 0.33 0.36 0.37 0.41 0.43 0.40 0.42 0.43 0.37 0.52 0.55 0.56 0.55 0.59 0.62
Amgen Inc. 3.21 3.36 3.09 2.73 2.84 3.05 2.71 2.40 2.31 2.28 1.40 1.11 1.11 1.11 1.16 1.15 1.10 1.20 1.12 1.14 1.16 1.14
Biogen Inc. 0.66 0.48 0.45 0.43 0.46 0.43 0.46 0.43 0.48 0.42 0.47 0.51 0.56 0.57 0.54 0.54 0.57 0.63 0.70 0.62 0.05 0.05
Bristol-Myers Squibb Co. 0.95 0.94 0.91 1.41 1.56 0.40 0.52 0.54 0.60 0.60 0.68 0.57 0.56 0.59 0.41 0.44 0.45 0.47 0.47 0.48 0.49 0.48
Eli Lilly & Co. 3.99 5.60 5.88 4.50 5.68 6.44 1.30 0.97 1.06 0.81 1.18 0.90 0.87 0.73 0.74 0.60 0.64 0.54 0.55 0.53 0.55 0.55
Gilead Sciences Inc. 1.34 1.09 1.09 1.19 1.15 1.21 1.28 1.19 1.34 1.41 1.64 1.18 1.16 1.29 1.39 1.60 1.42 1.70 1.20 1.28 0.75 0.72
Illumina Inc. 0.25 0.25 0.25 0.25 0.26 0.44 0.53 0.57 0.42 0.45 0.49 0.46 0.48 0.49 0.58 0.54 0.50 0.51 0.59 0.57 0.73 0.80
Johnson & Johnson 0.48 0.45 0.47 0.50 0.48 0.50 0.51 0.48 0.51 0.51 0.57 0.48 0.48 0.46 0.39 0.37 0.36 0.32 0.28 0.28 0.27 0.28
Merck & Co. Inc. 1.12 1.07 1.02 0.97 0.96 0.94 0.94 0.73 0.72 0.70 0.71 0.71 0.63 0.71 0.62 0.57 0.56 0.59 0.59 0.58 0.57 0.63
Pfizer Inc. 0.99 0.80 0.83 0.81 0.78 0.77 0.66 0.58 0.58 0.56 0.61 0.72 0.75 0.75 0.71 0.70 0.70 0.62 0.60 0.58 0.53 0.53
Vertex Pharmaceuticals Inc. 0.07 0.08 0.09 0.10 0.11 0.12 0.13 0.20 0.22 0.24 0.29 0.32 0.33 0.35 0.71 0.79 0.82 0.84 0.86 0.87 0.91 0.83
Zoetis Inc. 2.58 2.35 2.38 2.41 2.67 2.78 2.95 3.04 2.52 2.53 2.80 2.87 2.66 2.78 3.00 2.82 3.29 3.84 4.56 2.96 3.10 2.85

Based on: 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-05), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07).

1 Q2 2020 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity
= 2,215,900 ÷ 9,057,400 = 0.24

2 Click competitor name to see calculations.

Solvency ratio Description The company
Debt to equity ratio A solvency ratio calculated as total debt divided by total shareholders’ equity. Regeneron Pharmaceuticals Inc.’s debt to equity ratio improved from Q4 2019 to Q1 2020 but then deteriorated significantly from Q1 2020 to Q2 2020.

Debt to Capital

Regeneron Pharmaceuticals Inc., debt to capital calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in thousands)
Debt 1,500,000  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Finance lease liabilities, current portion —  —  —  —  —  —  —  —  —  —  —  —  —  7,200  129,557  —  —  —  —  —  —  — 
Finance lease liabilities, excluding current portion 715,900  715,200  713,900  712,700  711,300  709,900  708,500  707,203  705,903  704,645  703,453  702,317  701,173  700,407  351,569  382,228  361,523  362,230  362,919  364,144  357,687  328,394 
Convertible senior notes —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  30,723  30,360  144,082 
Total debt 2,215,900  715,200  713,900  712,700  711,300  709,900  708,500  707,203  705,903  704,645  703,453  702,317  701,173  707,607  481,126  382,228  361,523  362,230  362,919  394,867  388,047  472,476 
Stockholders’ equity 9,057,400  12,133,000  11,089,700  10,504,400  9,755,900  9,444,700  8,757,300  7,868,300  7,186,426  6,567,644  6,144,078  6,051,593  5,520,738  4,866,021  4,449,245  4,491,247  4,076,506  3,765,082  3,654,837  3,296,867  3,338,458  2,971,430 
Total capital 11,273,300  12,848,200  11,803,600  11,217,100  10,467,200  10,154,600  9,465,800  8,575,503  7,892,329  7,272,289  6,847,531  6,753,910  6,221,911  5,573,628  4,930,371  4,873,475  4,438,029  4,127,312  4,017,756  3,691,734  3,726,505  3,443,906 
Solvency Ratio
Debt to capital1 0.20 0.06 0.06 0.06 0.07 0.07 0.07 0.08 0.09 0.10 0.10 0.10 0.11 0.13 0.10 0.08 0.08 0.09 0.09 0.11 0.10 0.14
Benchmarks
Debt to Capital, Competitors2
Abbott Laboratories 0.39 0.38 0.37 0.38 0.38 0.38 0.39 0.43 0.40 0.41 0.47 0.43 0.43 0.43 0.52 0.29 0.30 0.29 0.30 0.28 0.28 0.29
AbbVie Inc. 0.86 1.12 1.14 1.27 1.30 1.27 1.27 1.08 1.10 0.91 0.88 0.85 0.86 0.88 0.89 0.85 0.87 0.87 0.89 0.87 0.85 0.92
Allergan PLC — 0.25 0.28 0.28 0.28 0.28 0.27 0.25 0.26 0.27 0.29 0.30 0.29 0.30 0.30 0.27 0.34 0.35 0.36 0.36 0.37 0.38
Amgen Inc. 0.76 0.77 0.76 0.73 0.74 0.75 0.73 0.71 0.70 0.69 0.58 0.53 0.53 0.53 0.54 0.53 0.52 0.54 0.53 0.53 0.54 0.53
Biogen Inc. 0.40 0.32 0.31 0.30 0.31 0.30 0.31 0.30 0.33 0.30 0.32 0.34 0.36 0.36 0.35 0.35 0.36 0.39 0.41 0.38 0.04 0.05
Bristol-Myers Squibb Co. 0.49 0.48 0.48 0.59 0.61 0.28 0.34 0.35 0.37 0.38 0.40 0.36 0.36 0.37 0.29 0.30 0.31 0.32 0.32 0.33 0.33 0.32
Eli Lilly & Co. 0.80 0.85 0.85 0.82 0.85 0.87 0.57 0.49 0.51 0.45 0.54 0.47 0.47 0.42 0.42 0.37 0.39 0.35 0.35 0.35 0.35 0.36
Gilead Sciences Inc. 0.57 0.52 0.52 0.54 0.54 0.55 0.56 0.54 0.57 0.59 0.62 0.54 0.54 0.56 0.58 0.62 0.59 0.63 0.54 0.56 0.43 0.42
Illumina Inc. 0.20 0.20 0.20 0.20 0.21 0.30 0.35 0.36 0.30 0.31 0.33 0.31 0.32 0.33 0.37 0.35 0.33 0.34 0.37 0.36 0.42 0.44
Johnson & Johnson 0.33 0.31 0.32 0.33 0.33 0.33 0.34 0.33 0.34 0.34 0.37 0.32 0.32 0.32 0.28 0.27 0.27 0.24 0.22 0.22 0.21 0.22
Merck & Co. Inc. 0.53 0.52 0.50 0.49 0.49 0.48 0.48 0.42 0.42 0.41 0.42 0.41 0.39 0.42 0.38 0.36 0.36 0.37 0.37 0.37 0.36 0.39
Pfizer Inc. 0.50 0.45 0.45 0.45 0.44 0.43 0.40 0.37 0.37 0.36 0.38 0.42 0.43 0.43 0.41 0.41 0.41 0.38 0.38 0.37 0.34 0.35
Vertex Pharmaceuticals Inc. 0.06 0.08 0.08 0.09 0.10 0.11 0.12 0.17 0.18 0.19 0.22 0.24 0.25 0.26 0.42 0.44 0.45 0.46 0.46 0.47 0.48 0.45
Zoetis Inc. 0.72 0.70 0.70 0.71 0.73 0.74 0.75 0.75 0.72 0.72 0.74 0.74 0.73 0.74 0.75 0.74 0.77 0.79 0.82 0.75 0.76 0.74

Based on: 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-05), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07).

1 Q2 2020 Calculation
Debt to capital = Total debt ÷ Total capital
= 2,215,900 ÷ 11,273,300 = 0.20

2 Click competitor name to see calculations.

Solvency ratio Description The company
Debt to capital ratio A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. Regeneron Pharmaceuticals Inc.’s debt to capital ratio improved from Q4 2019 to Q1 2020 but then deteriorated significantly from Q1 2020 to Q2 2020.

Debt to Assets

Regeneron Pharmaceuticals Inc., debt to assets calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in thousands)
Debt 1,500,000  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Finance lease liabilities, current portion —  —  —  —  —  —  —  —  —  —  —  —  —  7,200  129,557  —  —  —  —  —  —  — 
Finance lease liabilities, excluding current portion 715,900  715,200  713,900  712,700  711,300  709,900  708,500  707,203  705,903  704,645  703,453  702,317  701,173  700,407  351,569  382,228  361,523  362,230  362,919  364,144  357,687  328,394 
Convertible senior notes —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  30,723  30,360  144,082 
Total debt 2,215,900  715,200  713,900  712,700  711,300  709,900  708,500  707,203  705,903  704,645  703,453  702,317  701,173  707,607  481,126  382,228  361,523  362,230  362,919  394,867  388,047  472,476 
 
Total assets 14,428,700  15,757,500  14,805,200  13,939,300  13,173,600  12,854,800  11,734,500  10,805,613  9,951,980  9,372,696  8,764,286  8,701,215  8,106,373  7,817,365  6,973,466  6,828,019  6,204,906  5,904,460  5,609,132  5,182,915  4,526,970  4,198,573 
Solvency Ratio
Debt to assets1 0.15 0.05 0.05 0.05 0.05 0.06 0.06 0.07 0.07 0.08 0.08 0.08 0.09 0.09 0.07 0.06 0.06 0.06 0.06 0.08 0.09 0.11
Benchmarks
Debt to Assets, Competitors2
Abbott Laboratories 0.29 0.27 0.27 0.28 0.28 0.28 0.29 0.33 0.30 0.31 0.37 0.33 0.34 0.34 0.42 0.22 0.22 0.22 0.22 0.20 0.20 0.21
AbbVie Inc. 0.58 0.74 0.75 0.65 0.65 0.65 0.68 0.61 0.60 0.54 0.53 0.55 0.56 0.56 0.56 0.56 0.56 0.59 0.60 0.59 0.58 0.57
Allergan PLC — 0.22 0.24 0.24 0.24 0.24 0.23 0.22 0.23 0.24 0.25 0.25 0.24 0.25 0.25 0.23 0.30 0.31 0.31 0.30 0.31 0.32
Amgen Inc. 0.53 0.52 0.50 0.50 0.52 0.52 0.51 0.51 0.51 0.50 0.44 0.45 0.44 0.44 0.45 0.45 0.44 0.46 0.44 0.44 0.45 0.44
Biogen Inc. 0.29 0.23 0.22 0.22 0.23 0.22 0.23 0.23 0.25 0.23 0.25 0.28 0.30 0.31 0.28 0.30 0.30 0.32 0.33 0.32 0.03 0.04
Bristol-Myers Squibb Co. 0.36 0.36 0.36 0.43 0.45 0.17 0.21 0.22 0.23 0.23 0.24 0.25 0.25 0.26 0.20 0.20 0.21 0.21 0.21 0.23 0.23 0.22
Eli Lilly & Co. 0.39 0.42 0.39 0.40 0.41 0.42 0.29 0.28 0.29 0.26 0.30 0.31 0.30 0.27 0.27 0.25 0.26 0.23 0.22 0.22 0.22 0.23
Gilead Sciences Inc. 0.43 0.40 0.40 0.42 0.41 0.42 0.43 0.42 0.44 0.44 0.48 0.45 0.44 0.46 0.46 0.48 0.44 0.48 0.43 0.44 0.31 0.32
Illumina Inc. 0.16 0.16 0.16 0.16 0.16 0.24 0.29 0.29 0.23 0.24 0.25 0.26 0.27 0.27 0.30 0.29 0.26 0.27 0.30 0.30 0.35 0.37
Johnson & Johnson 0.19 0.18 0.18 0.19 0.19 0.20 0.20 0.20 0.21 0.21 0.22 0.23 0.23 0.22 0.19 0.19 0.19 0.17 0.15 0.15 0.15 0.15
Merck & Co. Inc. 0.34 0.33 0.31 0.31 0.32 0.31 0.30 0.28 0.27 0.27 0.28 0.29 0.27 0.29 0.26 0.26 0.25 0.26 0.26 0.26 0.26 0.28
Pfizer Inc. 0.36 0.31 0.31 0.31 0.30 0.29 0.26 0.24 0.25 0.25 0.25 0.26 0.26 0.26 0.25 0.25 0.26 0.24 0.23 0.23 0.22 0.22
Vertex Pharmaceuticals Inc. 0.05 0.06 0.06 0.07 0.08 0.09 0.09 0.12 0.13 0.15 0.16 0.18 0.17 0.18 0.28 0.31 0.32 0.32 0.32 0.33 0.34 0.38
Zoetis Inc. 0.59 0.56 0.56 0.57 0.59 0.59 0.60 0.62 0.58 0.57 0.58 0.61 0.59 0.58 0.58 0.58 0.59 0.60 0.62 0.54 0.55 0.57

Based on: 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-05), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07).

1 Q2 2020 Calculation
Debt to assets = Total debt ÷ Total assets
= 2,215,900 ÷ 14,428,700 = 0.15

2 Click competitor name to see calculations.

Solvency ratio Description The company
Debt to assets ratio A solvency ratio calculated as total debt divided by total assets. Regeneron Pharmaceuticals Inc.’s debt to assets ratio improved from Q4 2019 to Q1 2020 but then deteriorated significantly from Q1 2020 to Q2 2020.

Financial Leverage

Regeneron Pharmaceuticals Inc., financial leverage calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in thousands)
Total assets 14,428,700  15,757,500  14,805,200  13,939,300  13,173,600  12,854,800  11,734,500  10,805,613  9,951,980  9,372,696  8,764,286  8,701,215  8,106,373  7,817,365  6,973,466  6,828,019  6,204,906  5,904,460  5,609,132  5,182,915  4,526,970  4,198,573 
Stockholders’ equity 9,057,400  12,133,000  11,089,700  10,504,400  9,755,900  9,444,700  8,757,300  7,868,300  7,186,426  6,567,644  6,144,078  6,051,593  5,520,738  4,866,021  4,449,245  4,491,247  4,076,506  3,765,082  3,654,837  3,296,867  3,338,458  2,971,430 
Solvency Ratio
Financial leverage1 1.59 1.30 1.34 1.33 1.35 1.36 1.34 1.37 1.38 1.43 1.43 1.44 1.47 1.61 1.57 1.52 1.52 1.57 1.53 1.57 1.36 1.41
Benchmarks
Financial Leverage, Competitors2
Abbott Laboratories 2.25 2.21 2.18 2.15 2.16 2.19 2.20 2.33 2.24 2.26 2.47 2.26 2.25 2.26 2.56 1.90 1.93 1.91 1.94 1.98 1.92 1.97
AbbVie Inc. 10.17 — — — — — — — — 19.52 13.89 10.29 11.15 13.14 14.26 10.30 11.92 11.57 13.45 11.28 9.78 19.39
Allergan PLC — 1.52 1.63 1.61 1.60 1.59 1.56 1.51 1.53 1.55 1.60 1.67 1.66 1.69 1.69 1.60 1.73 1.76 1.77 1.84 1.92 1.95
Amgen Inc. 6.10 6.50 6.17 5.45 5.50 5.91 5.31 4.69 4.54 4.56 3.17 2.49 2.51 2.54 2.60 2.54 2.50 2.62 2.55 2.57 2.59 2.60
Biogen Inc. 2.26 2.08 2.04 1.96 2.03 1.91 1.94 1.85 1.95 1.86 1.88 1.79 1.88 1.85 1.88 1.82 1.89 2.00 2.08 1.96 1.33 1.30
Bristol-Myers Squibb Co. 2.61 2.59 2.52 3.25 3.44 2.29 2.49 2.47 2.65 2.59 2.86 2.30 2.27 2.28 2.08 2.16 2.20 2.22 2.23 2.11 2.11 2.16
Eli Lilly & Co. 10.25 13.35 15.07 11.20 13.91 15.32 4.47 3.41 3.67 3.05 3.88 2.89 2.90 2.68 2.77 2.41 2.49 2.31 2.44 2.39 2.46 2.39
Gilead Sciences Inc. 3.10 2.71 2.74 2.87 2.79 2.86 2.98 2.81 3.02 3.18 3.44 2.60 2.66 2.82 3.02 3.36 3.22 3.57 2.80 2.91 2.40 2.23
Illumina Inc. 1.59 1.57 1.59 1.60 1.61 1.85 1.85 1.93 1.80 1.84 1.91 1.77 1.79 1.80 1.95 1.89 1.94 1.91 1.99 1.93 2.06 2.16
Johnson & Johnson 2.51 2.53 2.65 2.67 2.55 2.54 2.56 2.41 2.47 2.48 2.61 2.10 2.12 2.06 2.01 1.93 1.93 1.88 1.88 1.86 1.86 1.89
Merck & Co. Inc. 3.28 3.24 3.26 3.10 3.04 2.99 3.09 2.63 2.61 2.56 2.56 2.40 2.35 2.42 2.38 2.25 2.23 2.25 2.28 2.22 2.21 2.27
Pfizer Inc. 2.77 2.56 2.65 2.62 2.62 2.64 2.51 2.35 2.36 2.25 2.41 2.83 2.89 2.89 2.88 2.82 2.72 2.58 2.59 2.56 2.40 2.39
Vertex Pharmaceuticals Inc. 1.36 1.38 1.37 1.43 1.39 1.39 1.41 1.59 1.61 1.65 1.75 1.79 1.97 1.96 2.50 2.55 2.60 2.60 2.66 2.64 2.65 2.22
Zoetis Inc. 4.38 4.19 4.26 4.21 4.56 4.70 4.93 4.94 4.37 4.43 4.85 4.67 4.55 4.75 5.14 4.87 5.54 6.40 7.41 5.44 5.61 5.03

Based on: 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-05), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07).

1 Q2 2020 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity
= 14,428,700 ÷ 9,057,400 = 1.59

2 Click competitor name to see calculations.

Solvency ratio Description The company
Financial leverage ratio A solvency ratio calculated as total assets divided by total shareholders’ equity. Regeneron Pharmaceuticals Inc.’s financial leverage ratio decreased from Q4 2019 to Q1 2020 but then increased from Q1 2020 to Q2 2020 exceeding Q4 2019 level.

Interest Coverage

Regeneron Pharmaceuticals Inc., interest coverage calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in thousands)
Net income 897,300  624,600  792,000  669,600  193,100  461,100  820,353  594,655  551,412  477,980  173,519  388,317  387,744  248,931  253,115  264,804  196,218  181,385  154,994  210,398  194,643  76,021 
Add: Income tax expense 21,600  44,000  97,800  98,900  31,600  85,000  (144,186) 41,206  104,662  107,418  381,248  177,288  138,106  183,358  88,412  101,077  96,038  148,766  72,295  182,891  133,353  200,502 
Add: Interest expense 9,700  6,100  6,700  7,800  8,000  7,700  7,349  7,494  6,918  6,439  6,035  6,182  5,401  7,501  3,082  222  1,251  2,640  3,609  1,715  2,748  6,169 
Earnings before interest and tax (EBIT) 928,600  674,700  896,500  776,300  232,700  553,800  683,516  643,355  662,992  591,837  560,802  571,787  531,251  439,790  344,609  366,103  293,507  332,791  230,898  395,004  330,744  282,692 
Solvency Ratio
Interest coverage1 108.12 90.22 81.43 72.82 69.19 86.34 91.55 91.46 93.35 93.76 83.75 85.15 103.77 119.78 185.82 158.42 135.89 120.37 87.03 — — —
Benchmarks
Interest Coverage, Competitors2
Abbott Laboratories 6.80 7.39 7.09 6.47 5.67 4.99 4.48 3.82 3.67 3.13 3.47 4.12 3.43 4.58 4.28 5.29 10.30 14.76 20.53 — — —
Allergan PLC — -4.39 -5.54 -11.84 -10.29 -8.70 -6.53 -0.74 -6.37 -6.82 -8.48 -8.86 -4.10 -3.33 -1.19 -1.14 -1.95 -1.87 -2.71 — — —
Amgen Inc. 7.62 7.85 8.09 7.97 7.63 7.61 7.86 7.98 8.35 8.41 8.36 8.44 8.46 8.25 8.27 8.23 8.30 8.35 8.29 — — —
Gilead Sciences Inc. 0.41 5.90 6.19 5.24 9.25 8.80 8.24 8.98 9.67 11.41 13.10 15.11 16.36 17.29 18.74 21.04 24.25 28.35 32.48 — — —
Illumina Inc. 21.05 23.15 22.50 18.34 16.69 15.85 16.68 19.94 20.81 20.03 29.19 28.79 29.69 30.05 17.91 18.67 15.73 14.19 14.84 — — —
Johnson & Johnson 81.36 81.56 55.49 34.61 29.04 20.98 18.91 17.95 18.54 18.77 19.92 24.03 25.69 27.08 28.28 28.40 29.56 33.95 35.78 — — —
Vertex Pharmaceuticals Inc. 40.26 30.99 24.84 12.91 13.16 11.02 9.28 11.26 3.07 0.05 0.73 -0.65 4.75 3.80 0.17 -1.01 -1.63 -3.67 -5.62 — — —
Zoetis Inc. 9.72 9.71 9.08 8.88 8.46 8.69 9.20 9.64 10.12 9.87 9.71 8.99 8.60 8.52 8.40 7.54 7.66 5.65 5.40 — — —

Based on: 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-05), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07).

1 Q2 2020 Calculation
Interest coverage = (EBITQ2 2020 + EBITQ1 2020 + EBITQ4 2019 + EBITQ3 2019) ÷ (Interest expenseQ2 2020 + Interest expenseQ1 2020 + Interest expenseQ4 2019 + Interest expenseQ3 2019)
= (928,600 + 674,700 + 896,500 + 776,300) ÷ (9,700 + 6,100 + 6,700 + 7,800) = 108.12

2 Click competitor name to see calculations.

Solvency ratio Description The company
Interest coverage ratio A solvency ratio calculated as EBIT divided by interest payments. Regeneron Pharmaceuticals Inc.’s interest coverage ratio improved from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.